Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female gender, age ≥ 18, postmenopausal.~* Histologically proven stage 0-III invasive carcinoma of the breast~* Initiating or have been receiving a standard dose of aromatase inhibitor therapy (letrozole 2.5mg once daily or exemestane 25mg once daily or anastrozole 1mg once daily) for up to a total of 48 months of AI therapy.~* Trouble sleeping during the past week. (After signing the informed consent document, subjects must also have a global PSQI score of ≥5)~* ECOG performance status 0-2 (see Appendix A).~Exclusion Criteria:~* Known hypersensitivity to cyclobenzaprine or any of the inactive ingredients~* Diagnosis of sleep apnea that is currently interfering with sleep or requiring CPAP, restless leg syndrome that is currently interfering with sleep or requiring medication, or Epworth sleepiness scale \>10.~* Subjects with a history of hypothyroidism must have been on a stable dose of thyroid replacement medicine for at least 3 months prior to enrollment~* Treatment with steroids within 1 month~* Treatment with monoamine oxidase inhibitors (MAO-I) within 14 days of enrollment.~* Concurrent treatment with bupropion, MAO inhibitors, phenothiazines (including thioridazine), selegiline, tramadol, or medications known to prolong the QT interval (www.azcert.org/medical-pros/drug-lists/drug-lists.cfm)~* Currently primary psychiatric diagnosis (schizophrenia, psychosis) or suicidal ideation, history of bipolar disorder, or seizure disorder~* Known moderate or severe hepatic impairment~* History of congestive heart failure or cardiac arrhythmia (other than atrial fibrillation); myocardial infarction within the past 6 months~* Uncontrolled narrow-angle glaucoma~* Pregnant or breast feeding~* Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclobenzaprine (Type: EXPERIMENTAL): Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).